The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses

The signal transduction pathway underlying the cAMP-dependent modulation of rat striatal N-methyl-D-aspartate (NMDA) responses was investigated by using the two-electrode voltage-clamp technique, In oocytes injected with rat striatal poly(A)(+) mRNA, activation of cAMP-dependent protein kinase (PKA) by forskolin potentiated NMDA responses, Inhibition of protein phosphatase 1 (PP1) and/or protein phosphatase 2A (PP2A) by the specific inhibitor calyculin A occluded the PKA-mediated potentiation of striatal NMDA responses, suggesting that the PKA effect was mediated by inhibition of a protein phosphatase. Coinjection of oocytes with striatal mRNA and antisense oligodeoxynucleotides directed against the protein phosphatase inhibitor DARPP-32 dramatically reduced the PKA enhancement of NMDA responses, NMDA responses recorded from oocytes injected with rat hippocampal poly(A)(+) mRNA were not affected by stimulation of PKA, When oocytes were coinjected with rat hippocampal poly(A)(+) mRNA plus complementary RNA coding for DARPP-32, NMDA responses were potentiated after stimulation of PKA, The results provide evidence that DARPP-32, which is enriched in the striatum, may participate in the signaling between the two major afferent striatal pathways, the glutamatergic and the dopaminergic projections, by the cAMP-dependent regulation of striatal NMDA currents.